BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 15042012)

  • 1. Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population?
    Chasen ST; McCullough LB; Chervenak FA
    Am J Obstet Gynecol; 2004 Mar; 190(3):769-74. PubMed ID: 15042012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuchal translucency and the acceptance of invasive prenatal chromosomal diagnosis in women aged 35 and older.
    Zoppi MA; Ibba RM; Putzolu M; Floris M; Monni G
    Obstet Gynecol; 2001 Jun; 97(6):916-20. PubMed ID: 11384696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population.
    Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia.
    Cheffins T; Chan A; Haan EA; Ranieri E; Ryall RG; Keane RJ; Byron-Scott R; Scott H; Gjerde EM; Nguyen AM; Ford JH; Sykes S
    BJOG; 2000 Dec; 107(12):1453-9. PubMed ID: 11192100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fetal chromosomal abnormalities: antenatal screening and diagnosis.
    Anderson CL; Brown CE
    Am Fam Physician; 2009 Jan; 79(2):117-23. PubMed ID: 19178062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Webbing of the neck and nasal bone--prenatal screening for Down syndrome].
    Svennekjaer S; Skibsted L
    Ugeskr Laeger; 2003 Apr; 165(17):1768-71. PubMed ID: 12768905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased nuchal translucency as a marker for fetal chromosomal defects.
    Taipale P; Hiilesmaa V; Salonen R; Ylöstalo P
    N Engl J Med; 1997 Dec; 337(23):1654-8. PubMed ID: 9385124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome.
    Lam YH; Lee CP; Sin SY; Tang R; Wong HS; Wong SF; Fong DY; Tang MH; Woo HH
    Prenat Diagn; 2002 Aug; 22(8):730-5. PubMed ID: 12210586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of fetal nuchal translucency.
    Jackson M; Rose NC
    Semin Roentgenol; 1998 Oct; 33(4):333-8. PubMed ID: 9800243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive prenatal diagnostic practice in Denmark 1996 to 2006.
    Vestergaard CH; Lidegaard Ø; Tabor A
    Acta Obstet Gynecol Scand; 2009; 88(3):362-5. PubMed ID: 19172424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of available prenatal screening and diagnosis: effects of the California screen program.
    Blumenfeld YJ; Taylor J; Lee HC; Hudgins L; Sung JF; El-Sayed YY
    J Perinatol; 2012 Dec; 32(12):907-12. PubMed ID: 22402484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of noninvasive prenatal testing at a large academic referral center.
    Larion S; Warsof SL; Romary L; Mlynarczyk M; Peleg D; Abuhamad AZ
    Am J Obstet Gynecol; 2014 Dec; 211(6):651.e1-7. PubMed ID: 24954652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuchal translucency screening: how do women actually utilize the results?
    Caughey AB; Musci TJ; Belluomini J; Main D; Otto C; Goldberg J
    Prenat Diagn; 2007 Feb; 27(2):119-23. PubMed ID: 17152116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based trends in invasive prenatal diagnosis for ultrasound-based indications: two decades of change from 1994 to 2016.
    Lostchuck E; Poulton A; Halliday J; Hui L
    Ultrasound Obstet Gynecol; 2019 Apr; 53(4):503-511. PubMed ID: 29877030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are age cutoffs still used to identify candidates for invasive testing for chromosomal abnormalities?
    Wasden SW; Adams BN; Chasen ST
    J Reprod Med; 2011; 56(3-4):113-6. PubMed ID: 21542527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of chromosome 22q11 analysis after detection of an increased first-trimester nuchal translucency.
    Hollis B; Mavrides E; Carvalho JS; Hill L; Dickinson V; Thilaganathan B
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):32-4. PubMed ID: 11489222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.